Addex Files Registration Statement on Form F-3 with the US Securities and Exchange Commission
08 April 2021 - 3:00PM
Geneva, Switzerland, April 8,
2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq:
ADXN), a clinical-stage pharmaceutical company pioneering
allosteric modulation-based drug discovery and development,
announced today that it has filed a registration statement on Form
F-3 with the U.S. Securities and Exchange Commission (SEC) to
provide flexibility for future offerings of shares, including those
to be settled in the form of American Depositary Shares (ADSs).
Each ADS represents the right to receive six shares of Addex. The
terms of the future offerings have not been determined yet and
there can be no assurance as to whether or when the offerings may
be completed. Addex intends to file a prospectus supplement with
the SEC, where required, to describe the specific terms of any such
securities offering.
A registration statement on Form F-3 has been
filed with the SEC but has not yet become effective. The securities
referred to in the registration statement may not be sold, nor may
offers to buy them be accepted, prior to the time the registration
statement becomes effective. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy
these securities, nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.
About Addex Therapeutics:Addex
Therapeutics is a clinical-stage pharmaceutical company
focused on the development and commercialization of an emerging
class of novel orally available small molecule drugs known as
allosteric modulators for neurological disorders. Allosteric
modulators offer several potential advantages over conventional
non-allosteric molecules and may offer an improved therapeutic
approach to conventional "orthosteric" small molecule or biological
drugs. Addex's allosteric modulator drug discovery platform targets
receptors and other proteins that are recognized as essential for
therapeutic intervention. Addex's lead drug candidate, dipraglurant
(mGlu5 negative allosteric modulator or NAM), is poised to start
a pivotal registration clinical trial for Parkinson’s disease
levodopa induced dyskinesia (PD-LID) in 2021. Addex is also
investigating dipraglurant's therapeutic use in blepharospasm (a
type of dystonia), for which a clinical trial is expected to be
initiated in 2021. Addex's third clinical program, ADX71149 (mGlu2
positive allosteric modulator or PAM), developed in collaboration
with Janssen Pharmaceuticals, Inc, is scheduled to enter a phase 2a
proof of concept clinical study for the treatment of epilepsy in
2021. Addex’s GABAB PAM program has been licensed to Indivior
PLC for the treatment of addiction. Preclinical programs include
GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild
neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and
mGlu3 PAM for neurodegenerative
disorders.
Press Contacts:
Tim DyerChief Executive OfficerTelephone: +41 22 884 15
55Email: PR@addextherapeutics.com |
Mike SinclairPartner, Halsin Partners+44 (0)20 7318
2955msinclair@halsin.com |
Forward Looking
Statements:Statements in this announcement concerning the
timing and terms of the anticipated offering of the Company’s
securities are forward-looking statements, which are subject to
risks and uncertainties, including those risks described in the
Company’s Annual Report on Form 20-F filed with the SEC on March
11, 2021, as well as market conditions and regulatory review.
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Apr 2024 to May 2024
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From May 2023 to May 2024